NCT03209921|Completed
Loading search results
Sponsor study identifier
observational
23
0 countries
N/A
Study Start
May 2015
Actual (reported)Primary Completion
September 2015
Actual (reported)Study Completion
September 2015
Actual (reported)Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society of America (IDSA) guidelines. The population pharmacokinetics (PK) of daptomycin have been described in various groups of patients in previous publications. However, little information exists on the PK of daptomycin in patients with bone and joint infections (BJI). Also, previous population studies did not investigate daptomycin PK over prolonged therapy, and, to our knowledge, no study has reported the intraindividual PK variability of this drug. The aim of this study is to describe the inter- and intraindividual PK variability of this drug.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2015
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2015
Actual (reported)September 2015
Actual (reported)September 2015
Actual (reported)July 4, 2017
Actual (reported)July 6, 2017
Actual (reported)Typical daptomycin clearance
Mean daptomycin plasma clearance (unit, liters per hour) Outcome measures performed regularly in those patients throughout therapy, roughly every month.
6 months
Typical daptomycin volume of distribution
Mean daptomycin volume of distribution (unit, liters) in the population
6 months
Patients treated with daptomycin for BJI in Lyon Center in 2012 and 2013
Contact the study team to confirm eligibility.
23 participants (actual enrollment reported by the registry).
First Submitted
July 4, 2017
First Posted
July 6, 2017
Study Start
May 2015
Actual (reported)Primary Completion
Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
September 2015
Actual (reported)Study Completion
September 2015
Actual (reported)Last Updated
July 6, 2017
Record last verified: 2017-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: